Before taking Truseltiq(Infigratinib)

Key warnings include risks of ocular toxicity, hyperphosphatemia leading to soft tissue mineralization, and embryo-fetal toxicity.

Warnings and Precautions

TRUSELTIQ carries a risk of causing retinal pigment epithelial detachment (RPED), necessitating comprehensive ophthalmological exams with optical coherence tomography prior to treatment, at 1 and 3 months, and then quarterly. It can induce hyperphosphatemia, which may lead to soft tissue mineralization; serum phosphate levels require regular monitoring and management with phosphate-lowering agents. The drug can cause fetal harm, mandating verification of pregnancy status in females of reproductive potential and advising the use of effective contraception during and for one month after treatment. Concomitant use with strong or moderate CYP3A inhibitors or inducers, and gastric acid-reducing agents, should be avoided.